Aptamer specifically binding to cell-derived extracellular vesicles and method for discovering extracellular vesicle-specific biomarker using same
Aptamers targeting colorectal cancer-derived extracellular vesicles address the limitations of current biomarker discovery methods by providing high sensitivity and reproducibility for identifying tumor-specific biomarkers, enhancing clinical application through EDGE-SELEX technology.
WO2026117034A1PCT designated stage Publication Date: 2026-06-04KONKUK UNIV IND COOP CORP
View PDF 0 Cites 0 Cited by
Patent Information
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- KONKUK UNIV IND COOP CORP
- Filing Date
- 2025-11-27
- Publication Date
- 2026-06-04
Smart Images
Figure KR2025019943_04062026_PF_FP_ABST
Abstract
The present invention relates to an aptamer specifically binding to cell-derived extracellular vesicles and a method for discovering an extracellular vesicle-specific biomarker using same. Specifically, the present invention relates to an aptamer specifically binding to cancer cell-derived extracellular vesicles, and a method for discovering an extracellular vesicle-specific biomarker using same. Unlike prior art requiring immobilization, a method for selecting an aptamer specifically binding to extracellular vesicles according to the present invention can select an aptamer specifically binding to extracellular vesicles that maintain a three-dimensional structure in an actual clinical environment. A biomarker discovery method using the aptamer selected through the selection method can be used to quickly and precisely identify unknown target proteins present in extracellular vesicles. The present invention can be efficiently applied to the fields of novel biomarker discovery, target protein verification for diagnosis, and aptamer-protein interaction-based drug development.
Need to check novelty before this filing date? Find Prior Art